POSOCCO, BIANCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.096
AS - Asia 1.977
EU - Europa 727
SA - Sud America 297
AF - Africa 272
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 11
Totale 5.401
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.918
SG - Singapore 602
VN - Vietnam 469
CN - Cina 322
BR - Brasile 195
HK - Hong Kong 144
IT - Italia 125
DE - Germania 104
BD - Bangladesh 99
FI - Finlandia 77
FR - Francia 53
IN - India 45
CA - Canada 39
PL - Polonia 39
GB - Regno Unito 36
RU - Federazione Russa 36
TR - Turchia 27
AR - Argentina 23
NL - Olanda 23
PK - Pakistan 22
ZA - Sudafrica 22
MX - Messico 19
UA - Ucraina 19
EC - Ecuador 18
SA - Arabia Saudita 18
AT - Austria 17
JP - Giappone 17
IQ - Iraq 16
KR - Corea 16
ID - Indonesia 15
PY - Paraguay 15
SE - Svezia 15
CO - Colombia 14
GE - Georgia 13
MA - Marocco 13
DK - Danimarca 12
HN - Honduras 12
BJ - Benin 11
CL - Cile 11
EG - Egitto 11
GT - Guatemala 11
BB - Barbados 10
HR - Croazia 10
KG - Kirghizistan 10
NI - Nicaragua 10
RO - Romania 10
AL - Albania 9
AO - Angola 9
IE - Irlanda 9
JO - Giordania 9
LV - Lettonia 9
ML - Mali 9
SN - Senegal 9
TH - Thailandia 9
YT - Mayotte 9
AD - Andorra 8
BA - Bosnia-Erzegovina 8
CV - Capo Verde 8
GN - Guinea 8
LA - Repubblica Popolare Democratica del Laos 8
MG - Madagascar 8
MY - Malesia 8
NP - Nepal 8
PH - Filippine 8
PT - Portogallo 8
RE - Reunion 8
BF - Burkina Faso 7
BY - Bielorussia 7
CG - Congo 7
CI - Costa d'Avorio 7
CW - ???statistics.table.value.countryCode.CW??? 7
DO - Repubblica Dominicana 7
DZ - Algeria 7
GM - Gambi 7
IL - Israele 7
LU - Lussemburgo 7
MD - Moldavia 7
PS - Palestinian Territory 7
TT - Trinidad e Tobago 7
UZ - Uzbekistan 7
AZ - Azerbaigian 6
BZ - Belize 6
CR - Costa Rica 6
CZ - Repubblica Ceca 6
ES - Italia 6
ET - Etiopia 6
GP - Guadalupe 6
GR - Grecia 6
IR - Iran 6
JM - Giamaica 6
KE - Kenya 6
LT - Lituania 6
LY - Libia 6
MK - Macedonia 6
MN - Mongolia 6
MR - Mauritania 6
NA - Namibia 6
NZ - Nuova Zelanda 6
PA - Panama 6
PE - Perù 6
Totale 5.150
Salva come PNG Salva come JPEG
Città #
Ashburn 415
Singapore 408
San Jose 326
Ho Chi Minh City 154
Hanoi 137
Hong Kong 133
Fairfield 104
Chandler 85
Beijing 84
Munich 68
Santa Clara 61
Houston 47
New York 47
Cambridge 41
Seattle 41
Ann Arbor 40
Los Angeles 40
Helsinki 38
Boardman 35
Woodbridge 34
Buffalo 29
Bytom 29
Lauterbourg 27
Wilmington 27
Da Nang 22
São Paulo 22
Turku 21
San Diego 19
Chicago 18
Dallas 17
Guangzhou 15
Medford 14
Princeton 14
London 13
Montreal 13
Orem 13
Haiphong 12
Hefei 12
Tokyo 12
Toronto 12
Cotonou 11
Council Bluffs 11
Johannesburg 11
Milan 11
Bridgetown 10
Chennai 10
Managua 10
Vienna 10
Bishkek 9
Bến Tre 9
Falkenstein 9
Jeddah 9
Lahore 9
Amman 8
Andorra la Vella 8
Biên Hòa 8
Brooklyn 8
Cairo 8
Conakry 8
Dakar 8
Guayaquil 8
Hải Dương 8
Kyiv 8
Riga 8
Rio de Janeiro 8
Rome 8
San Francisco 8
Trieste 8
Amsterdam 7
Ankara 7
Baghdad 7
Des Moines 7
Luanda 7
Minsk 7
Naples 7
Praia 7
Tirana 7
Abidjan 6
Baku 6
Bamako 6
Brazzaville 6
Copenhagen 6
Frankfurt am Main 6
Guatemala City 6
Kampala 6
Kigali 6
Lappeenranta 6
Luxembourg 6
Nairobi 6
Nha Trang 6
Ninh Bình 6
Nouakchott 6
Panama City 6
Thái Bình 6
Ulan Bator 6
Vientiane 6
Auckland 5
Boston 5
Cape Town 5
Castries 5
Totale 3.145
Salva come PNG Salva come JPEG
Nome #
Field-assisted paper spray mass spectrometry for therapeutic drug monitoring: 1. the case of imatinib in plasma 245
Cross-validation of a mass spectrometric-based method for the therapeutic drug monitoring of irinotecan: implementation of matrix-assisted laser desorption/ionization mass spectrometry in pharmacokinetic measurements 225
A new high-performance liquid chromatography–tandem mass spectrometry method for the determination of sunitinib and N-desethyl sunitinib in human plasma: Light-induced isomerism overtaking towards therapeutic drug monitoring in clinical routine 225
NPQ activation reduces chlorophyll triplet state formation in the moss Physcomitrella patens 216
A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer 216
Exploring pharmacokinetic variability of palbociclib in HR+/HER2- metastatic breast cancer: a focus on age, renal function, and drug-gene interactions 203
Light driven water oxidation by a single site cobalt salophen catalyst 202
Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis 201
A LC–MS/MS method for therapeutic drug monitoring of sorafenib, regorafenib and their active metabolites in patients with hepatocellular carcinoma 197
Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application 190
Analytical aspects of sunitinib and its geometric isomerism towards therapeutic drug monitoring in clinical routine 186
The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure 184
An SPR investigation into the therapeutic drug monitoring of the anticancer drug imatinib with selective aptamers operating in human plasma 181
Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients 179
Dried Blood Spot Technique Applied in Therapeutic Drug Monitoring of Anticancer Drugs: a Review on Conversion Methods to Correlate Plasma and Dried Blood Spot Concentrations 173
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer 171
Field-assisted paper spray mass spectrometry for the quantitative evaluation of imatinib levels in plasma 170
Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method 169
Bioanalytical Methods for Poly(ADP-Ribose) Polymerase Inhibitor Quantification: A Review for Therapeutic Drug Monitoring 166
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer 165
A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring 163
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure 159
A new LC-MS/MS method for the simultaneous quantification of abemaciclib, its main active metabolites M2 and M20, and letrozole for therapeutic drug monitoring 157
Increased plasma imatinib exposure and toxicity in chronically treated GIST patients with SARS-CoV-2 infection: a case series 153
Mass spectrometry in the pharmacokinetic studies of anticancer natural products 150
Therapeutic drug monitoring of palbociclib, ribociclib and letrozole in women with breast cancer by LC-MS 149
Quantification of Letrozole, Palbociclib, Ribociclib, Abemaciclib, and Metabolites in Volumetric Dried Blood Spots: Development and Validation of an LC-MS/MS Method for Therapeutic Drug Monitoring 145
LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring 142
The development of a matrix-assisted laser desorption/ionization (MALDI)-based analytical method for determination of irinotecan levels in human plasma: Preliminary results 137
A fast and validated LC-MS/MS method to quantify lenvatinib in dried blood spot 125
Matrix-assisted laser desorption/ionization, nanostructure-assisted laser desorption/ionization and carbon nanohorns in the detection of antineoplastic drugs. 1. The cases of irinotecan, sunitinib and 6-alpha-hydroxy paclitaxel 88
Totale 5.432
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.643
article - articoli 15.643
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.286
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215 0 0 0 0 0 0 0 0 0 0 0 5
2021/2022184 8 20 13 11 4 28 10 16 9 14 15 36
2022/2023185 25 22 3 26 32 17 0 9 28 4 13 6
2023/2024122 6 16 6 11 9 27 11 6 10 3 11 6
2024/2025905 1 79 40 36 77 52 30 83 44 44 146 273
2025/20263.694 216 218 461 457 379 150 639 313 377 207 216 61
Totale 5.432